50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
A general explainer on why the body holds onto its large fat reserves even though they carry tens of thousands of calories.
26:51
A full day of low carb, high protein eating from Roseland Lashay as she shifts into maintenance on tirzepatide.
19:08
A physician on YouTube makes the case that GLP-1 drugs like Ozempic and Mounjaro, plus trial drug retatrutide, are misunderstood when framed as weight loss drugs.
9:11
Physician Dr Almerie talks through retatrutide and the effects it may have past the number on the scale.
11:28
Liz cooks her meals for the day, runs through her skincare and catches viewers up on life 50 lbs into Wegovy.
8:28
A weight loss doctor walks through retatrutide, which she calls the most anticipated obesity drug currently in clinical trials.
27:23
A UK vlogger taking oral semaglutide checks in on the first week at the higher 25mg dose of the Wegovy pill.
Dr. Madz Abraham went on NET 25 with host Kada Umaga to talk through the science behind collagen peptides. A skincare angle on the peptide conversation.
An educational social post from Dr. Levine sorting which diabetes medications he rates best and which he flags as concerns.
17:56
DOWNSIZED looks at EASD 2026 data on an amylin-based drug reaching 23% weight loss and how it might stack up against retatrutide.
10:44
A personal account of a month on retatrutide, a drug still in trials and not approved for sale. It amounts to one person's anecdote, with no sourcing given.
DrAlo points to a 20% drop in heart attacks and strokes among patients on a weight loss drug, people who did not have diabetes.
A French clip flags dry mouth and reflux in GLP-1 patients, plus a specific risk to watch for before sedation.
A GP shares her own weight loss story and the long stretch of difficulty that came before the results people now see.
Doctor Devine says more patients on GLP-1 weight loss drugs are coming in with concerns, though the specific issue is cut off.
A brief share flagging a study on GLP-1 medications and overdose as the opioid epidemic shifts, with few details given beyond the link.
A TikTok playlist from iamkamiam_ collects clips about a personal GLP-1 journey and injection days. Little else is given about what the videos cover.
10:40
A clinic channel's short take on what tirzepatide does inside the body. No description came with it, so expect a general overview rather than new findings.
Local news team runs a verify segment on retatrutide, the experimental weight-loss drug people are buying without approval.
16:36
Fitness coach Mike Thurston gives his personal opinion on peptides after using them for several months. His views are his own, not medical advice.
3:15
CBS News reports two deaths tied to an unregulated weight-loss drug sold outside approved channels. The full investigation has the details.
28:35
An animated look at how many people are taking retatrutide before any approval, and what that means for the gray market.
9:11
A short clip weighing the approved tirzepatide against retatrutide, which is still in trials, for people over 50.
27:27
Becky Reynolds covers her three-month update on oral Wegovy, with food hauls and how she handled eating on a cruise.
17:54
Dr. Stirrett weighs the two drugs against each other for people over 50 trying to lose weight.
13:00
A short video on what else people may be losing besides fat while on tirzepatide, a point raised often around muscle loss on GLP-1 drugs.
Loading…